Newcells Biotech is Drug Discovery in United Kingdom that focus on lung that business. Founded in 2014. They cover business area such as developer, in vitro cell-base assay, early drug discovery, development, building model, liver, lung, prediction, safety, pharmacology, efficacy, human, kidney and retina platform, class, launch, stem cell-base model, researcher, new drug, screen potential drug molecule, toxicity.
2014
( 10 years old in 2024 )
Lung That
-
The Biosphere Drayman's Way
Newcastle Helix
Newcastle Upon Tyne NE4 5BX
England, United Kingdom
Private
developerin vitro cell-base assayearly drug discoverydevelopmentbuilding modelliverlungpredictionsafetypharmacologyefficacyhumankidney and retina platformclasslaunchstem cell-base modelresearchernew drugscreen potential drug moleculetoxicity
* We use standard office opening hours in near Newcells Biotech's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Newcells Biotech is Drug Discovery business from United Kingdom that founded in 2014 (10 years old in 2024), Newcells Biotech business is focusing on Lung That.
Newcells Biotech headquarter office and corporate office address is located in The Biosphere Drayman's Way Newcastle Helix Newcastle Upon Tyne NE4 5BX England, United Kingdom.
Newcells Biotech was founded in United Kingdom.
In 2024, Newcells Biotech is currently focus on lung that sector.
Above is snippet of Google Trends for "lung that" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Newcells Biotech, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
